SecBot SecBot
Institutional Cluster

IDYA

IDEAYA Biosciences, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed13d 13h ago
Institutional cluster: 4 buyers, 0 sellers (bullish)
Actionable Insight • Neutral

The institutional buying is modest in scale relative to the $3.2B market cap and is not corroborated by insider buying (confluence score 11/100, divergent). Monitor the upcoming FDA decision on darovasertib and the next 10-Q for cash burn and pipeline updates.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$31.33
T+0 close · Nov 3, 2026 · via day close
Latest settled
+1.34%
T+5 · $31.75 · next T+20 in 15d
Vs SPY
+1.93%
α at T+5
Latest observation
−1.57%
T+9 · FF3 residual α
  1. T+0 · Nov 3 $31.33entry
  2. T+1 · 13d ago +3.29%α +1.64% · $32.36
  3. T+5 · 7d ago +1.34%α +1.93% · $31.75
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Four institutional asset managers added to their IDYA positions in Q3 2026, collectively increasing holdings by $3.3M to a total of $12.4M. The buying follows the company's NDA submission for darovasertib in metastatic uveal melanoma and the closure of the Phase 3 OptimUM-010 trial, which is expected to save $100-125M for reallocation to other pipeline programs. No institutional selling was reported in the cluster.

Key Financial Metrics

Direction
accumulating
Buy Value
$12.4M
Net Flow
$3.3M

Institutional Positions

Net institutional flow: $3.3M

▲ Buyers (4)

InstitutionActionChangePosition ValueValue Δ
Mirae Asset Global Investments Co.ADD+25.5%$189.0K$43.0K
Strs OhioADD+26.3%$1.6M$381.0K
Alps AdvisorsADD+44%$4.9M$1.6M
Congress Asset ManagementADD+25.5%$5.7M$1.3M

Key Facts

  • 4 institutional buyers added $3.3M in aggregate, with total holdings of $12.4M
  • No institutional sellers in the cluster
  • NDA submission for darovasertib in metastatic uveal melanoma completed
  • Phase 3 OptimUM-010 trial closed, expected to save $100-125M
  • Cash at $1.15B with runway into 2030 unchanged
  • Confluence score 11/100 (divergent), no open-market insider buying

Financial Impact

4 institutions added $3.3M in net new positions, totaling $12.4M in current holdings

institutional ownership

Risk Factors

  • 13F data is 45+ days stale; positions may have been unwound since quarter-end
  • No insider buying to corroborate institutional conviction
  • All buyers are asset managers, not specialist biotech funds, signal is moderate
  • Regulatory risk on darovasertib NDA outcome

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-IDYA-2026-Q3

Track record

13 reports on IDYA

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Viewing Entry $31.33 to $31.75 ▲ +1.34% +1.93% vs SPY
  2. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 ▲ +1.34% +1.93% vs SPY
  3. Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 ▲ +6.62% +5.64% vs SPY
  4. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 ▲ +2.02% +2.12% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 ▼ −0.30% −2.01% vs SPY
  6. Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 ▼ −8.39% −7.96% vs SPY
  7. Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 ▼ −10.76% −7.33% vs SPY
  8. Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 ▼ −7.70% −5.28% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 ▼ −2.82% +1.00% vs SPY
  10. May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 ▼ −2.16% −3.29% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 9h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026